**Mast cells promote pathology and susceptibility in tuberculosis**

Ananya Gupta[1,2], Vibha Taneja[1], Javier Rangel Moreno[3], Abhimanyu[1], Mushtaq Ahmed[1],

Nilofer Naqvi[1], Kuldeep S. Chauhan[1], Daniela Trejo-Ponce de León[5,6], Gustavo Ramírez-

Martínez[6], Luis Jiménez-Alvarez[6], Cesar Luna-Rivero[6], Joaquin Zuniga[5,6], Deepak Kaushal[6],

Shabaana A. Khader[1,2#]

Affiliations:

[1] The University of Chicago, Department of Microbiology, 920 East 58th Street, CLSC 1117,

Chicago, IL 60637.

[2] Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO

63110, USA

[3] Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of

Rochester Medical Center, Rochester, NY, USA

[5] Technologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Mexico City,

Mexico

[6] Laboratory of Immunobiology and Genetics and Department of Pathology, Instituto Nacional

de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico

[7] Texas Biomedical Research Institute, San Antonio, Texas 78245-0549, USA.

[#] Correspondence:

Shabaana A. Khader, The University of Chicago, Department of Microbiology, 920 East 58th

Street, CLSC 1117, Chicago, IL 60637, Phone: (773)-702-2601. Email-khader@uchicago.edu

**Abstract**

Tuberculosis (TB), caused by the bacterium *Mycobacterium tuberculosis* (*Mtb*), infects approximately one-fourth of the world's population. While most infected individuals are asymptomatic, latent TB infection (LTBI) can progress to cause pulmonary TB (PTB). We recently reported an increased accumulation of mast cells (MCs) in lungs of macaques with PTB, compared with LTBI in macaques. MCs respond in vitro to *Mtb* exposure via degranulation and by inducing proinflammatory cytokines. In the current study, we show the dominant production of chymase by MCs in granulomas of humans and macaques with PTB. Using scRNA seq analysis, we show that MCs found in LTBI and healthy lungs in macaques are enriched in genes involved in tumor necrosis factor alpha, cholesterol and transforming growth factor beta signaling. In contrast, MCs clusters found in PTB express transcriptional signatures associated with interferon gamma, oxidative phosphorylation, and MYC signaling. Additionally, MC deficiency in the mouse model showed improved control of *Mtb* infection that coincided with reduced accumulation of lung myeloid cells and diminished inflammation at chronic stages. Thus, these collective results provide novel evidence for the pathological contribution of MCs during *Mtb* infection and may represent a novel target for host directive therapy for TB.

**Keywords:** Mast cells, Tuberculosis, lung, innate cell, inflammation.

**Introduction.** Tuberculosis (TB) remains a significant global health issue, with approximately one-quarter of the world's population harboring *Mycobacterium tuberculosis* (*Mtb*) causing around 1.5 million deaths each year (WHO, 2023). The disease often starts as a latent TB infection (LTBI), in which the bacteria remain dormant and cause no symptoms. However, LTBI can progress to active pulmonary TB (PTB), characterized by severe respiratory symptoms and high transmission potential. The immune mechanisms that allow progression from latent to PTB are not fully defined. Thus, understanding the immune factors that drive progression toward PTB will allow the development of novel therapeutics for TB control. Towards this overall goal, we recently showed that the lung single-cell transcriptional immune landscape during LTBI and PTB in macaques infected with *Mtb* was distinct. For example, PTB was characterized by the significant accumulation of Type I IFN expressing-plasmacytoid DCs (pDCs), IFN-responsive macrophages as well as activated T cells to the lungs, (Esaulova *et al*., 2021). Additionally, mast cells (MCs) were increased in the lungs of macaques with PTB (Esaulova *et al*., 2021). In sharp contrast, LTBI was characterized by increased presence of cytotoxic NK cells but lack of recruitment of MCs in the lungs (Esaulova *et al*., 2021).

MCs are found in the lung where they influence inflammatory responses (Naqvi *et al*., 2021). MCs have been shown to respond *in vitro* to *Mtb* exposure via surface receptors such as CD48 (Munoz *et al*., 2003). They also react to *Mtb* exposure or mycobacterial lipids by undergoing degranulation of prestored granules such as histamine and β-hexosaminidase, and inducing secretion of proinflammatory cytokines such as IL-6 and TNF-α (Munoz *et al.,* 2003). Degranulation of MCs following intratracheal infection with a high dose of *Mtb* resulted in limiting inflammation and proinflammatory cytokines such as IL-1β and TNF-α (Carlos *et al*., 2007). MCs produce and release either chymase or tryptase (Bian *et al*., 2021) which are both proteases that are stored in the cell's secretory granules. Recent studies with lung biopsies of TB patients showed an enrichment of MCs expressing IL-17 at inflammatory sites. In contrast,

chymase rich MCs (MC$_C$s) producing TGF-β were detected in proximity to mature granulomas

in lung biopsies from PTB (Garcia-Rodriguez *et al*., 2021). Furthermore, while healthy lung

predominantly has tryptase-expressing mast cells (MC$_T$s), both chymase and dual mast cells

co-expressing chymase and tryptase (MC$_C$s and MC$_{TC}$s) accumulate in the infected lung of

patients with PTB (Garcia-Rodriguez *et al*., 2021). Thus, while previous studies have shown

that MCs respond to *Mtb* exposure and accumulate in macaque and human lungs during PTB,

it is not completely known if MCs functionally mediate protective or pathological outcomes in

the context of TB infection.

In the current study, we show that the distribution and localization of MCs in PTB in humans

and macaques is associated with chymase production. Using scRNA seq analysis, we show that

MCs found in LTBI and healthy lungs in macaques, are transcriptionally distinct than PTB

lungs showing enrichment of tumor necrosis factor alpha, cholesterol and transforming growth

factor beta signaling, while MCs found in PTB express increased levels of signatures associated

with interferon gamma, oxidative phosphorylation, and MYC signaling. Additionally, mice

deficient in MCs, showed improved control of *Mtb* infection and reduced lung inflammation,

providing novel evidence that chymase positive MCs contribute to immune pathology and

reduced *Mtb* control, suggesting a pathological role for MCs during *Mtb* infection.

**Materials and methods**

**Study subjects**

All human lung biopsy samples were obtained from the Tuberculosis Outpatient Clinic and the

Department of Pathology at the National Institute of Respiratory Diseases (INER) in Mexico

City, before *M. tuberculosis* treatment with informed consent, and with the approved protocol

by the INER IRB for their use (project numbers B04-15 and B09-23). Also, lung samples from

healthy controls (HC) non-TB individuals were obtained from the tissue repository of the

Department of Pathology from INER. No compensation was provided to the patients.

Non-human primate procedures were approved by the Institutional Animal Care and Use

Committee of Tulane National Primate Research Center and were performed in accordance

with National Institutes of Health (NIH) guidelines. Male and female Indian rhesus macaques,

verified to be free of *Mtb* infection by tuberculin skin test, were obtained from the Tulane

National Primate Research Center. The animals were housed in an ABSL3 facility.

C57Bl/6 and B6.Cg-KitW-sh/HNihrJaeBsmJ (Strain #:030764) alias $CgKitW^{sh}$ mice were

procured from Jackson Laboratory (Bar Harbor, ME) and bred at Washington University in St.

Louis. Six to eight weeks female and male mice were used in the experiments. All mice were

maintained and used in accordance with the approved Institutional Animal Care and Use

Committee (IACUC) guidelines at Washington University in St. Louis.

**Aerosol Infection**

*Mtb* strain HN878 was cultured in Proskauer Beck medium containing 0.05% Tween 80 until

reaching mid-log phase and frozen in 1 ml aliquots at -80°C until used. Mice were aerosol

infected with ~100 colony forming units (CFU), as described previously (Khader *et al*., 2007).

Macaques were assigned to three groups: (1) uninfected control, (2) macaques with LTBI were

exposed to a low dose (~10 CFU), and (3) macaques with PTB were exposed to a high dose

(~100 CFU) of *Mtb* CDC1551 via the aerosol route using a custom head-only dynamic

inhalation system housed within a class III biological safety cabinet as previously described

(Esaulova *et al*., 2021). The animals were periodically monitored for detecting alterations in

their physiological parameters and to monitor disease symptoms.

**Bacterial burden and cytokine Analysis**

Bacterial burden was assessed using serial 10-fold dilutions of lung or spleen homogenates and

plated on 7H11 agar solid medium supplemented with OADC (oleic acid, bovine albumin,

dextrose, and catalase). Colonies were counted after 2-3 weeks of incubation.

Cytokine/chemokine expression was analyzed in lung homogenates from infected mice via

Luminex (Millipore-Sigma) or ELISA (R&D) as per the manufacturer's protocol.

**124    Generation of single-cell suspensions from tissues and flow cytometry staining**

Lung single-cell suspensions from *Mtb*-infected mice were prepared as previously described

(Gopal *et al*., 2013). Briefly, mice were euthanized with $CO_2$. The right lower lobe was isolated

and perfused with heparin in saline. Lungs were minced and incubated with

collagenase/DNAse for 30 minutes at 37°C. Lung tissue was pushed through a 70μm nylon

screen to obtain a single cell suspension. Following lysis of erythrocytes, the cells were washed

and resuspended in cDMEM (DMEM high glucose + 10% fetal bovine serum + 1%

Penicillin/Streptomycin) for flow cytometry staining. For flow cytometric analysis, cells were

either stained immediately, or stimulated with phorbol myristate acetate (PMA-50ng/ml;

Sigma Aldrich) and ionomycin (750 ng/ml; Sigma Aldrich) in the presence of Golgistop (BD

Pharmingen).

The following fluorochrome conjugated antibodies were used for myeloid cell surface staining

CD11b APC (clone M1 / 70), CD11c PeCy7 (clone HL3, BD Biosciences) GR-1 PerCP-Cy5.5

(Clone RB6-8C5, BD Pharmingen) and MHC class II FITC (Clone M5/114.15.2, Tonbo

Biosciences), Anti-Mo CD117 (cKit) super bright 780 (eBiosciences; clone 2BB), FcεR1 PE

(eBiosciences; clone MAR-1). Myeloid cells: alveolar macrophages were gated on

$CD11c^+CD11b^-$, neutrophils were defined as $CD11b^+CD11c^-Gr-1^{hi}$ cells, monocytes were

defined as $CD11b^+CD11c^-Gr-1^{med}$ cells, recruited macrophages were defined as

$CD11b^+CD11c^-Gr-1^{low}$ cells and mast cells were defined as $CD11b^-cKit^+FcεR1^+$ cells. T cells

were identified based on gating strategy as described before (Griffiths *et al*., 2016). CD3

AF700 (clone 500A2, BD Biosciences), CD4 Pacific blue (clone RM4.5, BD Biosciences),

CD44 PeCy7 (clone 1M7, Tonbo Biosciences), CD8 APC Cy7 (clone 53-6.7, BD Biosciences)

were used for T-cell surface staining. Fixation/permeabilization concentrate and diluent

(eBioscience) were used in the intracellular stain to fix and permeabilize lung cells following

manufacturer's instructions. Intracellular staining was performed with IFNγ APC (clone

XMG1.2, Tonbo Biosciences) and TNF-α -FITC (Clone MP6-XT22, BD Pharmingen) or the

respective isotype control antibodies (APC rat IgG1κ and FITC rat IgG1α isotype, BD

Pharmingen) for 30 min. Samples were acquired on a 4 laser BD Fortessa Flow Cytometer and

the analysis was performed using FlowJo (Treestar). Total numbers of cells within each gate

were back calculated based on cell counts in the individual lung samples.

**Histological analysis**

For mice studies, the left upper lobe was collected for histomorphometric analysis. The lobes

were infused with 10% neutral buffered formalin and embedded in paraffin. 5 μm thick ling

sections were cut using a microtome, stained with hematoxylin and eosin (H&E) and processed

for light microscopy. Images were captured using the automated Nanozoomer digital whole

slide imaging system (Hamamatsu Photonics). Regions of inflammatory cell infiltration were

delineated utilizing the NDP view2 software (Hamamatsu Photonics), and the percentage of

inflammation was calculated by dividing the inflammatory area by the total area of individual

lung lobes. All scoring was conducted in a blinded manner.

FFPE lung sections from healthy individuals, tuberculosis patients and NHP infected with *MTB*

were stained with goat anti-human mast cell chymase (LifeSpan Biosciences, LS-B4134,

RRID:AB_10718418) and rabbit anti-human tryptase (Cell Signaling Technology, 195235).

Primary antibodies were detected with Alexa fluor 568 donkey anti-goat Ig G (Thermo Fisher

Scientific, A-11057, RRID:AB_2534104) and Alexa Fluor 488 donkey anti-rabbit Ig G

(Jackson ImmunoResearch Laboratories, 711-546-152, RRID:AB_2340619). Nuclei were

labeled with DAPI. MC positive for chymase, tryptase or both were blindly quantitated in 3

200x random fields per sample in human and NHP lung sections. 200x pictures were taken

with an Axioplan Zeiss microscope and recorded with a Hamamatsu camera.

**Data analysis and statistics**

All data was analyzed using the indicated methodology in each figure legend. Two sided-

unpaired t-test was performed for comparing significance between 2 groups, one-way ANOVA

Tukey's test and two-way ANOVA Sidak's multiple comparison test were performed for more

than 2 groups using GraphPad Prism 5 and 10, respectively (La Jolla, CA). Significance is

denoted on the figure and the respective figure legends. Outliers, if any, were removed using

Grubb's outlier test and mentioned in the respective figures.

**Single cell data reanalysis**

The NHP single cell lung data was accessed from GEO (GSE149758) and processed through

*cellranger 7.0* using the Macaca Mulatta reference genome (Mmul_10). The obtained matrix

file was processed through the R package *Seuratv- 5* for downstream analysis of the count

matrix. The cells were filtered based on mitochondrial gene content and at least 500 genes

detected. Data was log normalized. The most variable genes were detected by the

*FindVariableFeatures* function and used for subsequent analysis. Latent variables (number of

UMI's and mitochondrial content) were regressed out using a negative binomial model

(function *ScaleData*). Principle component analysis (PCA) was performed with the *RunPCA*

function. A UMAP dimensionality reduction was performed on the scaled matrix (with most

variable genes only) using the first 20 PCA components to obtain a two-dimensional

representation of the cell states. For clustering, we used the functions *FindNeighbors* (20 PCA)

and *FindClusters* (resolution 0.25).  MCs were identified and re-clustered based on expression

of the canonical MC marker genes *FCER1A* (High affinity Fc IgE receptor), *CD48*, *FCER1G*

(Fc IgE receptor), *MS4A2* (IgE subunit) and *ITGAX* (CD11c) as a negative marker. The cells

identified MC cluster (only one cluster) were subset and re-clustered using the method outlined

above at a resolution of 0.1. To identify marker genes for mast cells, we used *FindAllMarkers*

to compare cluster against all other clusters, and *FindMarkers* to compare selected clusters.

For each cluster, only genes that were expressed in more than 15% of cells with at least 0.15-

fold differences were considered. The differential genes were subjected to enrichment analysis

using Hallmark Pathway gene set from *MsigDB*. The pathways that met an FDR threshold less

than 0.05 were considered.

Gene signatures were defined with R package *Ucell*. The output is a module signature score

generated by *AddModuleScore* function. The obtained score was overlaid on the UMAP and

visualized. The Values per cell were extracted and used to plot a summed module U cell score.

GraphPad prism was used for the Violin plots and the heatmap. All other figures were

generated in R.

**Results**

**Mast cells localize and transition phenotypes within TB granulomas**

$MC_T$s were primarily found within the lung from healthy controls (HC), while $MC_C$s or $MC_{TC}$s

were found in the lung biopsies of patients with PTB (Garcia-Rodriguez *et al*., 2021). To

validate these observations and analyze the compartmentalization of MCs in human lungs, we

stained lung biopsies from healthy individuals and patients with PTB to visualize the spatial

distribution of $MC_C$s, $MC_T$s and $MC_{TC}$s. Our results show that $MC_C$s are not well represented

in the lung parenchyma, interstitium, vasculature, or bronchus of HC lungs (Figure 1A, Figure

S1). Instead, we observed that the healthy lungs predominantly contain MC$_T$s and, to a lesser

extent, MC$_{TCS}$. While MC$_{TCS}$ accumulated in early immature granulomas within TB lesions,

MC$_C$s accumulated in late granuloma in TB patients (Figure 1A and B). MC$_T$s also increased

in the interstitium, vasculature and bronchus-associated lymphoid tissue of patients with PTB

(Figure S1A). Therefore, our study confirmed that MC$_T$s are found in HCs (Garcia-Rodriguez

*et al.*, 2021) and likely convert first to MC$_{TCS}$ in early granulomas before becoming MC$_C$s in

late mature granulomas with necrotic cores.

Our published data showed that MCs accumulate in the lungs of macaques with PTB compared

to LTBI macaque lungs (Esaulova *et al.*, 2021). Thus, we next analyzed the accumulation and

localization of MCs in the lungs of macaques with LTBI and PTB. We found that similar to

human healthy lungs, MC$_T$s accumulated in the lungs of healthy macaques. Although MC$_T$s

and these cells increased in some lesions in the lungs of macaques with LTBI, the number of

MC$_T$s in macaques with PTB were significantly increased in all sites including granuloma

(Figure 1C and D), interstitium as well as vasculature (Figure S1B). Additionally, while MC$_{TCS}$

increased in the granulomas of macaques with PTB compared to the lungs of macaques with

LTBI and HCs, we did not observe any increase of these cells in other sites within the lung

compared to healthy macaques. No MC$_C$s were measurable within macaque lungs. Our data

indicate an accumulation of MC$_T$s but not MC$_{TCS}$ during LTBI. However, as the disease

progresses to PTB, there is an increase in both MC$_{TCS}$ and additional MC$_T$s.

**Lung mast cells express inflammatory and metabolically active transcriptome in**

**macaques with PTB**

To further understand the transcriptional differences between MCs in lungs of HCs, LTBI and

PTB, we re-analyzed the MC subpopulation in the scRNA seq data from macaques from

Esaulova *et al*. We examined the single-cell transcriptome of 500 mast cells with unsupervised

clustering and identified four clusters, three of which (0,1,3) belonged to PTB group and cluster

2 was found exclusively in LTBI and HC (Figure 2A). All the MC clusters were positive for

markers such as *FCER1A* (high-affinity IgE receptor), *MS4A2* (IgE subunit), *CD48* (mast cell

receptor) and negative for markers like *ITGAX* (macrophage/dendritic cell marker) (Figure 2B).

Differential expressed genes (DEGs) among the cluster revealed cluster specific markers.

Among the top 10 genes of the largest PTB cluster 0 were *CENPA* (metabolic reprogramming

related centromeric protein, (Liang *et al.*, 2021)), *NEK2*, *MELK2* (NF-kB regulator), (Zhang

*et al*., 2022)), *CDC20* (role in LC3 mediated autophagy; (Xie *et al*., 2018)), *CDCA5*, *GTSE1*,

*CDCA3, ASPM* (proliferation related, (Shen *et al*., 2021), ASPM; (Kouprina *et al*., 2005)), and

*BIRC5* (Immunosuppressive and infiltration-associated), genes that were upregulated in MCs

from PTB compared to MCs from LTBI and HC lungs. Similarly, the transcriptome of the cells

from LTBI and HC expressed high levels of *TUBB6* (inhibitor of pyroptosis, (Salinas *et al*.,

2014)), *CD9-1*, *TNFRSF12A* (TNF receptor, needed for anti-TB immunity), *DUSP4,*

*HMGCS1*, *LMNA*, *MARCKSL1*, *PHLDA1*, *RGCC* as compared to PTB clusters. The other PTB

clusters expressed genes such as *FANCE*, *IL18R1*, *FOS*, *CYTB*, *IL3RA* are genes related to

activated mast cells (Figure 2C). Enrichment of cluster specific DEGs revealed enrichment of

cholesterol, TNF-α, and TGFβ signaling in LTBI. Oxidative phosphorylation, and IFNγ

signaling, and MYC signaling were enriched in the PTB group (Figure 2D). Plotting the

summed *Ucell* module scores revealed significant upregulation of IFNγ signaling, Oxidative

Phosphorylation and Th2 signature in PTB ($P < 0.05$), while LTBI and HC clusters showed

enhanced TNF signaling ($P < 0.05$) (Figure 2E-H). Since we observed increased chymase in

MCs of PTB (Figure 1A), we used a chymase signature to compare the PTB with LTBI / HC

mast cells. The MCs from PTB (Cluster 0) expressed high levels of chymase, confirming the

immunostaining results (Figure 1A). Thus, this analysis provides evidence for the

transcriptional heterogeneity in the MCs derived from PTB and LTBI and shows differential

activation programs in the cell based on the disease state.

**MC deficient mice exhibit enhanced control of _Mtb_**

We next determined if MCs are induced in response to infection in mice following aerosolized

low dose _Mtb_ infection, and whether they accumulate early or later in infection. Our prior

results have shown that innate cells such as ILCs accumulate very early between days 5-10 and

followed by accumulation of other innate cells such as neutrophils, macrophages and

monocytes between days 10-15 and T cells by day 21 to 30 (Ardain _et al._, 2019). We found

that MCs accumulate in the lung at time points between day 21 and 30 and coincide with timing

of accumulation of T cells in the lung (data not shown).

To further investigate the functional role of MCs in _Mtb_ infection, we utilized MC deficient

mouse model, _CgKitW^{sh}_. Mice carrying spontaneous loss-of-function mutations at both alleles

of the dominant _white spotting_ (_W_) locus (_i.e._, c-_kit_) exhibit a marked reduction in c-_kit_ tyrosine

kinase-dependent signaling resulting in dysregulated mast cell development, survival and

function (Wolters _et al._, 2005). We infected _CgKitW^{sh}_ mice with low dose aerosolized _Mtb_

HN878 and found that compared with wild type control _Mtb_-infected mice, _CgKitW^{sh}_ mice did

not show any differences in _Mtb_ CFU at early time points (50 days post infection (dpi), (Figure

3A). However, at later time points (100 dpi and 150 dpi), _CgKitW^{sh} Mtb_-infected mice showed

significantly lower lung _Mtb_ CFU, when compared with _Mtb_-infected wild type control mice

(Figure 3B). This coincided with reduced inflammation in the lungs of _CgKitW^{sh} Mtb_-infected

mice at 150 dpi (Figure 3D and E). Additionally, no differences in _Mtb_ CFU were observed at

50 dpi in the spleen, _CgKitW^{sh} Mtb_-infected mice showed enhanced control of _Mtb_ in the spleen

at 100 and 150 dpi (Figure 3C). Therefore, _CgKitW^{sh}_ mice lacking MCs exhibit better _Mtb_

control, specifically during late stages of infection.

To mechanistically address the functional basis of enhanced protection, we analyzed the lungs

of *CgKitW^sh* mice before and after *Mtb* infection as this mouse strain is associated with other

known immune deficiencies (Grimbaldeston *et al*., 2005). At baseline, MCs were significantly

reduced in the lungs of *CgKitW^sh* mice compared to B6 mice. MCs continued to accumulate in

the lung up to 100 dpi in *CgKitW^sh* mice, following which the MC numbers decreased at later

stages. Indeed, the deficiency in MCs observed in lungs of *CgKitW^sh* mice was retained

following infection until 150 dpi (Figure 4A). However, we also found that at baseline

*CgKitW^sh* mice also showed increased dendritic cells (DCs) as well as recruited macrophages

(RMs) but no perturbations in alveolar macrophages (AMs), neutrophils or monocytes.

Additionally, the increased DCs and RMs responses were also evident in *CgKitW^sh* mice at 50

dpi following infection, but not maintained at later time points (Figure 4B and C). No

differences in AMs, neutrophils and monocytes were observed in the lungs of *Mtb*-infected

*CgKitW^sh* mice when compared with *Mtb*-infected control mice at all time points tested (Figure

D, E and F). Previous studies have implicated MCs in driving T cell responses (Elieh *et al*.,

2018). At baseline, we found that there is an increase in $CD4^+$ and $CD8^+$ T cells numbers (data

not shown), we found no differences in $CD4^+$ and $CD8^+$ T cells responses at 50 dpi, but

numbers of activated $CD4^+$ and $CD8^+$ T cells were significantly reduced at 100dpi, which

compromised $CD4^+$ IFNγ producing cells as well as TNF-α and IFNγ dual cytokine producing

subsets at 100 dpi, in the *CgKitW^sh* mice as compared to C57Bl/6 *Mtb*-infected mice (Figure

S2). Finally, we measured cytokine responses in the lungs of wild type C57Bl/6 and *CgKitW^sh*

*Mtb*-infected mice at 150 dpi. We found that while proinflammatory cytokines that direct

monocyte/macrophage responses and T cell responses  including G-CSF, IFNγ, IL-1β, IL-6,

IL-17, MCP-1, TNF-α and RANTES were significantly higher  in wild type *Mtb*-infected lungs

compared with *CgKitW^sh Mtb* infected lungs, chemokines that direct neutrophil responses such

as MIP-1α, MIP-1β, KC and MIP2 and Th2 cytokines like IL-13 were not different between

wild type and *CgKitW^{sh}* *Mtb*-infected lungs at 150 dpi (Figure 4G). These results together

provide evidence that MCs are induced following *Mtb* infection, accumulate in the lung and

mediate cytokine responses to drive pathology and promote *Mtb* susceptibility and

dissemination during TB.

**Discussion**

The immune mechanism(s) that mediate the progression from LTBI to PTB are unclear. In this

study, we identified MCs as an innate cell type that is overrepresented during PTB,

transcriptionally express signatures associated with IFNγ, oxidative phosphorylation, and

MYC signaling, and localize within mature TB granulomas. Importantly, using mice deficient

in MCs, we show a potential pathological role for MCs in mediating susceptibility to TB.

Together, this paper provides evidence of MCs in the context of pathology and susceptibility

to TB providing MCs as a novel therapeutic platform.

MCs have been shown to interact with *Mtb* through the GPI anchored molecule CD48 (Munoz

*et al*., 2003), interaction with TLR2 (Carlos *et al*., 2007) and potentially TLR4 (McCurdy, Lin,

& Marshall, 2001). Additionally, *Mtb* is also thought to be internalized by lipid rafts on MCs

(Munoz *et al*., 2009), thus serving as a long lasting reservoir for *Mtb* (da Silva *et al.,* 2014).  In

in vitro studies, MC exposure to *Mtb* resulted in degranulation of MCs as well as induction of

proinflammatory cytokines such as TNF-α and IL-1β. While these studies using high dose

model of infection reported early induction of inflammatory mediators from MC within hours

to days, our in vivo results using a physiological low dose of *Mtb* infection model show that

MCs accumulate between 21-30 days coinciding with accumulation of T cells in the lung.

Interestingly, despite accumulation of MCs in the lung at 30 dpi following low dose aerosol

infection, the impact of MC deficiency on *Mtb* control and inflammation in *CgKitW^{sh}* mice is

not evident until 100 dpi. This is similar to our published studies where we found that S100A8/9

deficiency resulted in reduced neutrophil lung accumulation (Scott *et al*., 2020), resulted in

improved *Mtb* control and improved TB disease, but after 100 dpi. This is in contrast to the

role of eosinophils in TB, where eosinophil deficiency resulted in increased *Mtb* CFU (Bohrer

*et al*., 2021). MCs are the primary cell type defective in the lungs of *CgKitW$^{sh}$* mice at baseline

and at all time points following infection, thus, we attribute the improved *Mtb* control with MC

deficiency. However, we do report increased RMs and DCs accumulation at baseline in

*CgKitW$^{sh}$* mice, but these changes are not maintained until 100 dpi, a time point when we see

impact on *Mtb* control. Additionally, the reduced inflammation observed at 100 and 150 dpi is

associated with decreased level of proinflammatory cytokines and chemokines that recruit

monocytes/macrophages and T cells, but not chemokines that are associated with neutrophil

recruitment. These results imply an important role for MCs in amplifying

macrophage/monocyte accumulation during chronic TB and driving increased lung pathology.

Overall, based on our results along with the current literature, we propose pathological roles

for neutrophils and MCs, while other granulocytes such as eosinophils may mediate protective

roles (Bohrer *et al*., 2021).

MCs can release cytokines and chemokines, antimicrobial peptides and granules upon

pathogen sensing and to control pathogens (Naqvi *et al.,* 2020). In the context of *Mtb* exposure,

MCs have been shown to undergo degranulation including histamine and β-hexosaminidase

(Munoz *et al*., 2003). Indeed, histamine deficient mice showed decreased neutrophils, as well

as proinflammatory cytokine production following *Mtb* infection (Carlos *et al*., 2009).

Additionally, induction of degranulation following intratracheal *Mtb* infection resulted in

reduced proinflammatory cytokines as well as reduced lung inflammation. With respect to

*CgKitW$^{sh}$ Mtb*-infected mice, except lower numbers of DCs and CD4$^{+}$ and CD8$^{+}$ T cell

responses at 100 dpi, we did not find any significant differences in accumulation of innate or

adaptive myeloid populations in the lung at other time points. Incidentally decreased numbers

of DCs and T cells at 100 dpi was reflected with reduced lung inflammation at 100 dpi. Thus,

together with published work, while MCs can potentially modulate neutrophil and other

inflammatory mediators in high dose models, in a physiologically relevant *Mtb* infection

model, absence of MCs impacted late TB disease and improved *Mtb* control without significant

changes to other innate cells. The exact mechanism by which MCs contributing to pathology,

dissemination and promoting *Mtb* is an area of future investigation.

At baseline, human lungs have been reported to primarily express tryptase (Poto *et al*., 2022)

Indeed, we found that this is true for both macaque and human lungs in our study where healthy

lungs expressed $MC_T$s. Additionally, we found that early granulomas and in LTBI we saw

expression of $MC_{TC}$s with a switch to more and accumulation of $MC_C$s in late stage

granulomas. Chymase expression may modulate extracellular matrix components (ECM) such

as fibronectin leading to tissue remodeling, impacting cellular communication and inducing

cleavage for key cytokine such as IL-6, IL-13, IL-15, and IL-33, as well as Transforming

Growth Factor (TGF-β) (Pejler, 2020; Waern *et al*., 2013). Studies have shown that tryptase

can induce proliferation of fibroblasts, epithelial cells and smooth muscle cells, causing airway

remodeling during diseased conditions (Mogren *et al*., 2021). Tryptase can also inactivate a

large range of peptides by cleaving specific substrates, such as fibrinogen, gelatin, pro-matrix

metalloproteinases (MMP) and complement factors thus moderating inflammatory responses

(Caughey, 2007). Based on our results from human and macaque lung, we hypothesize that

$MC_{TC}$s may synergize to drive responses induced by both pathways at early time points and

possibly just by $MC_C$s at later time points. Additional studies describing these subsets and

testing their functional relevance in *in vivo* models are future steps in delineating the role of

these subsets in TB.

Analysis of the single cell transcriptome from lungs of macaques identified that the MCs from

PTB animals show closer resemblance to $MC_C$s with higher IFNγ, metabolic activation and

expression of *CMTA* gene and chymase signature, although all the MCs (from PTB, LTBI and

HC) had a minimal tryptase signature. MCs are known to gear towards a Th2 signature with

increased chymase expression (Toru *et al*., 1998). This increase was reflected in MCs from the

macaque lung, showing a high transcriptomic Th2 signature in PTB but not in clusters found

in LTBI and HC. In essence transcriptomics reflected the hyperactivated nature of the MCs in

PTB, which might make them more pathologic during infection. Although our *in vivo* mouse

study shows pathological role of MCs, significant secretion of Th2 cytokines are not seen,

likely because the C57Bl/6 mouse model is prone towards Th1 polarization (Wakeham, *et al*.,

2000). MCs have the ability to release both preformed and de novo synthesized TNF-α, hence

helping in early bacterial clearance (Gordon and Galli, 1991). Similarly, our study shows that

the MCs from HC and LTBI individuals expressed higher levels of TNF-α, and in less-

metabolically activated state (lower OXPHOS signature). So additional studies will help in

elucidating the mechanism through which MCs mediate pathological roles.

In summary, we demonstrate that accumulation of chymase producing MC in PTB is a cross-

species phenomenon that contributes to increased TB pathology and loss of TB control, thereby

elucidating the pathological role of MCs in the control of *Mtb* infection. By targeting MC

pathways or signaling mechanisms, host-directed therapies (HDTs) hold the promise of

enhancing the effectiveness of existing treatments and mitigating disease-related

complications.

**Acknowledgements**

This work was supported by Washington University in St. Louis; NIH grant HL105427, AI111914, AI134236 and AI123780 to S.A.K., and the Department of Microbiology, University of Chicago. We thank Ms. Lan Lu, Washington University in St. Louis and Ms. Tao Yun, University of Chicago for technical support and assistance.

**Authors Contributions**

S.A.K supervised all aspects of the study. A.G. designed, performed experiments, and analyzed data. A.G., V.T., A.A., and K.S.C. curated data and constructed figures. V.T, J.R.M, M.A., N.N. and K.S.C. contributed resources and/or data analysis. A.G. and S.A.K wrote the original draft of the manuscript. A.G., A.A., N.N., V.T., and S.A.K. reviewed and edited the manuscript. J.Z. provided human specimen. D.K. provided NHP specimen, D.K and S.A.K provided funding. All authors reviewed, edited and approved the manuscript.

**Competing interests.**

The authors declare no competing interests.

**<u>References</u>**

Ardain A, Domingo-Gonzalez R, Das S, Kazer S W, Howard NC, Singh A, Khader SA.

2019. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.

*Nature* **570**: 528-532. DOI: https://doi.org/10.1038/s41586-019-1276-2, PMID: 31168092

Bian G, Gu Y, Xu C, Yang W, Pan X, Chen Y, Ma F. 2021. Early development and

functional properties of tryptase/chymase double-positive mast cells from human pluripotent

stem cells. *Journal of Molecular  Cell Biology* **13**: 104-115. DOI:

https://doi.org/10.1093/jmcb/mjaa059, PMID: 33125075

Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Mayer-Barbe KD.

2021. Eosinophils are part of the granulocyte response in tuberculosis and promote host

resistance in mice. *Journal of Experimental Medicine* **218**. DOI:

https://doi.org/10.1084/jem.20210469, PMID:  34347010

Carlos D, de Souza Junior DA, de Paula L, Jamur MC, Oliver C, Ramos SG, Faccioli LH.

2007. Mast cells modulate pulmonary acute inflammation and host defense in a murine

model of tuberculosis. *Journal of Infectious Diseases* **196**: 1361-1368. DOI:

https://doi.org/10.1086/521830, PMID: 34347010

Carlos D, Fremond C, Samarina A, Vasseur V, Maillet I, Ramos SG, Ryffel B. 2009.

Histamine plays an essential regulatory role in lung inflammation and protective immunity in

the acute phase of Mycobacterium tuberculosis infection. *Infection and Immunity* **77**: 5359-

5368. DOI: https://doi.org/10.1128/IAI.01497-08, PMID: 19822651

Caughey GH. 2007. Mast cell tryptases and chymases in inflammation and host defense.

*Immunological Reviews* **217**: 141-154. DOI: https://doi.org/10.1111/j.1600

065X.2007.00509.x, PMID: 17498057

da Silva EZ, Jamur MC,Oliver C. 2014. Mast cell function: a new vision of an old cell.

*Journal of Histochemistry Cytochemistry* **62**:698-738. DOI:

https://doi.org/10.1369/0022155414545334, PMID: 25062998

Esaulova E, Das S, Singh DK, Choreno-Parra JA, Swain A, Arthur L, Khader, SA. 2021. The

immune landscape in tuberculosis reveals populations linked to disease and latency. *Cell*

*Host and Microbe* **29**: 165-178 e168. DOI: https://doi.org/10.1016/j.chom.2020.11.013,

PMID: 33340449

Elieh AKD, Grauwet K. 2018. Role of Mast Cells in Regulation of T Cell Responses in

Experimental and Clinical Settings. *Clinical Reviews in  Allergy and Immunology* **54**: 432-

445.DOI:  https://doi.org/10.1007/s12016-017-8646-z, PMID: PMID: 28929455

Garcia-Rodriguez KM, Bini EI, Gamboa-Dominguez A, Espitia-Pinzon CI, Huerta-Yepez S,

Bulfone-Paus S, Hernandez-Pando R. 2021. Differential mast cell numbers and

characteristics in human tuberculosis pulmonary lesions. *Scientific  Reports* **11**: 10687. DOI:

https://doi.org/10.1038/s41598-021-89659-6, PMID: 34021178

Gopal R, Rangel-Moreno J, Slight S, Lin Y, Nawar HF, Fallert Junecko BA,  Khader, SA.

2013. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity

against tuberculosis. *Mucosal Immunology* **6**: 972-984. DOI:

https://doi.org/10.1038/mi.2012.135, PMID: 23299616

• Griffiths, K., Ahmed, M., Das, S., Gopal, R., Horne, W., Connell, TD., Moynihan, KD.,

Kolls, JK., Irvine, DJ., Artyomov, MN., Rangel-Moreno, J., Khader, SA. 2016. Targeting

dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine

efficacy. *Nature Communications* **7**: 13894. DOI: https://doi.org/10.1038/ncomms13894,

PMID: 28004802

Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. 2005. Mast cell-

deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell

biology in vivo. *The American Journal of Pathology* **167**: 835-848.DOI:

https://doi.org/10.1016/S0002-9440(10)62055-X, PMID: 16127161

Gordon J R, Galli S J. 1991. Release of both preformed and newly synthesized tumor

necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc

epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-

dependent biological responses. *Journal of Experimental Medicine* **174**: 103-107. DOI:

https://doi.org/10.1084/jem.174.1.103, PMID: 1829107

Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Cooper AM. 2007.

IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after

vaccination and during Mycobacterium tuberculosis challenge. *Nature Immunolog,* **8**:369-

377. DOI: https://doi.org/10.1038/ni1449, PMID: 17351619

Kouprina N, Pavlicek A, Collins NK, Nakano M, Noskov VN, Ohzeki J, Larionov V. 2005.

The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic

spindle protein. *Human Molecular Genetics* **14**:2155-2165. DOI:

https://doi.org/10.1093/hmg/ddi220, PMID: 15972725

Liang YC, Su Q, Liu YJ, Xiao H,Yin HZ. 2021. Centromere Protein A (CENPA) Regulates

Metabolic Reprogramming in the Colon Cancer Cells by Transcriptionally Activating

Karyopherin Subunit Alpha 2 (KPNA2). *American  Journal of Pathology* **191**:2117-2132.

DOI: https://doi.org/10.1016/j.ajpath.2021.08.010, PMID: 34508688

McCurdy JD, Lin TJ, Marshall, JS. 2001. Toll-like receptor 4-mediated activation of murine

mast cells. *Journal of Leukocyte Biology* **70**: 977-984. PMID: 11739561

Mogren S, Berlin F, Ramu S, Sverrild A, Porsbjerg C, Uller L, Andersson CK. 2021. Mast

cell tryptase enhances wound healing by promoting migration in human bronchial epithelial

cells. *Cell Adhesion and Migration* **15**, 202-214. DOI: https://doi.org/

10.1080/19336918.2021.1950594, PMID: 34308764

Munoz S, Hernandez-Pando R, Abraham SN, Enciso JA. 2003. Mast cell activation by

Mycobacterium tuberculosis: mediator release and role of CD48. *Journal of Immunology*

**170:**5590-5596. DOI: https://doi.org/10.4049/jimmunol.170.11.5590, PMID: 12759438

Munoz S, Rivas-Santiago B, Enciso JA. 2009. Mycobacterium tuberculosis entry into mast

cells through cholesterol-rich membrane microdomains. *Scandavian Journal of Immunology*

**70**:256-263. DOI: https://doi.org/10.1111/j.1365-3083.2009.02295.x, PMID: 19703015

Naqvi N, Srivastava R, Naskar P, Puri N. 2021. Mast cells modulate early responses to

Mycobacterium bovis Bacillus Calmette-Guerin by phagocytosis and formation of

extracellular traps. *Cellular Immunology* **365**: 104380. DOI:

https://doi.org/10.1016/j.cellimm.2021.104380, PMID: 34049012

Naqvi N, Srivastava R, Selvapandiyan A, Puri N. 2020. Host Mast Cells in Leishmaniasis:

Friend or Foe? *Trends of Parasitology* **36**: 952-956. DOI:

https://doi.org/10.1016/j.pt.2020.09.010, PMID: 33060062

World Health Organization, 2023. Global Tuberculosis Report Retrieved from

https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-

report-2023.

Pejler G. 2020. Novel Insight into the in vivo Function of Mast Cell Chymase: Lessons from

Knockouts and Inhibitors. *Journal of Innate Immunology* **12**: 357-372. DOI:

https://doi.org/10.1159/000506985, PMID: 32498069

Poto R, Criscuolo G, Marone G, Brightling CE, Varricchi G.2022. Human Lung Mast Cells:

Therapeutic Implications in Asthma. *International Journal of Molecular Sciences* **23**. DOI:

https://doi.org/10.3390/ijms232214466, PMID: 36430941

Salinas RE, Ogohara C, Thomas MI, Shukla KP, Miller SI, Ko DC. 2014. A cellular genome

wide association study reveals human variation in microtubule stability and a role in

inflammatory cell death. *Molecular Biology of the Cell* **25**:76-86. DOI:

https://doi.org/10.1091/mbc.E13-06-0294, PMID: 24173717

Scott NR, Swanson RV, Al-Hammadi N, Domingo-Gonzalez R, Rangel-Moreno J, Kriel BA,

Khader SA. 2020. S100A8/A9 regulates CD11b expression and neutrophil recruitment during

chronic tuberculosis. *Journal of Clinical Investigation,* **130**: 3098-3112. DOI:

https://doi.org/10.1172/JCI130546, PMID: 32134742

Shen D, Fang Y, Zhou F, Deng Z, Qian K, Wang G, Wang X. 2021. The inhibitory effect of

silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma. *Cancer*

*Cell International* **21**: 257. DOI: https://doi.org/10.1186/s12935-021-01969-x,

PMID: 33980246

Toru H, Eguchi M, Matsumoto R, Yanagida M, Yata J, Nakahata T. 1998. Interleukin-4

promotes the development of tryptase and chymase double-positive human mast cells

accompanied by cell maturation. *Blood,* **91**:187-195. PMID: 9414284

Waern I, Lundequist A, Pejler G, Wernersson S. 2013. Mast cell chymase modulates IL-33

levels and controls allergic sensitization in dust-mite induced airway inflammation. *Mucosal*

*Immunol* **6**: 911-920. DOI: https://doi.org/10.1038/mi.2012.129, PMID: 23235745

Wakeham J, Wang J, Xing Z. 2000. Genetically determined disparate innate and adaptive

cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in

C57BL/6 and BALB/c mice. *Infection and Immunity,* **68**:6946-6953. DOI:

https://doi.org/10.1128/IAI.68.12.6946-6953.2000, PMID: 11083818

Wolters PJ, Mallen-St Clair J, Lewis CC, Villalta SA, Baluk P, Erle DJ, Caughey GH. 2005.

Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-

deficient $Kit^{(W-sh)}/Kit^{(W-sh)}$ sash mice. *Clinical and Experimental Allergy,* **35**: 82-88. DOI:

https://doi.org/10.1111/j.1365-2222.2005.02136.x, PMID: 15649271

Xie YP, Lai S, Lin QY, Xie X., Liao JW, Wang HX, Li HH. 2018. CDC20 regulates cardiac

hypertrophy via targeting LC3-dependent autophagy. *Theranostics* **8:** 5995-6007. DOI:

https://doi.org/10.7150/thno.27706, PMID: 30613277

Zhang Y, Lu R, Huang X, Yin E, Yang Y, Yi C, Yuan, X. 2022. Circular RNA MELK

Promotes Chondrocyte Apoptosis and Inhibits Autophagy in Osteoarthritis by Regulating

MYD88/NF-kappaB Signaling Axis through MicroRNA-497-5p. *Contrast Media Molecular*

*Imaging* **2022**: 7614497. DOI: https://doi.org/10.1155/2022/7614497, PMID: 35992546

 **Figure legends**

 **Figure 1. Chymase positive mast cells are predominant in TB infected human and**

**macaque lung tissue.** Lung biopsies from healthy individuals (n = 4) or patients with PTB (n

= 5) were stained for tryptase $MC_T$ (green) or chymase $MC_C$ (red). (A) Immunofluorescence

microscopy shows $MC_{TS}$ (green) in healthy lung biopsies (HC). $MC_{TCS}$ (red and green merge)

are located around the early granulomas, while $MC_{CS}$ (red) surround the late granulomas in TB

infected lung biopsies. (B) Predominance of $MC_{TS}$ in healthy lungs transitioning to $MC_{TCS}$ in

early granuloma and becoming $MC_{CS}$ in late granulomas in TB infected lungs. (C)

Immunofluorescence microscopy shows $MC_{TS}$ (green) and $MC_{TCS}$ (merge) in lungs of healthy

(HC), LTBI and PTB macaques. (D) Predominance of $MC_{TS}$ (green) and $MC_{TCS}$ (merge) in

PTB compared to LTBI and HC. Statistical analysis was performed using unpaired, 2-tailed

Student's t test, **** $p < 0.0001$, *** $p < 0.001$, * $p < 0.05$.

**Figure 2. Mast cells in lung in active TB show an inflammatory and metabolically active**

**transcriptome as compared to HC or LTBI.** Single-cell (sc) RNA-seq Data was re-analyzed

from the lung of non-human primates (Esauolva *et al*). (A) UMAP embedding of the *FCER1A*+

mast cells, revealed four transcriptionally distinct clusters; the distribution of the MCs across

disease condition is indicated by the color PTB (pink), HC (green) and LTBI (blue). (B)

Showing the average expression of MCs specific marker genes (*FCER1A*, *MS4A2* and *CD48*)

and a macrophage gene *ITGAX* in contrast. (C) Dot plot indicating expression of top

differentially expressed genes detected for each cell cluster identified. The dot color represents

the expression level, and the dot size represents the percentage of cells in each cluster

expressing a particular gene. (D) Hallmark Pathway analysis of the differential genes, only top

pathways with highest FDR in each cluster is plotted. The color indicates the –log10 FDR; E-

H) UMAP plots with the U cell module score (averaged score of all genes) of the pathways

and their corresponding violin plots. Cluster 2 from LTBI/HC were compared to the rest of the

PTB groups using a Kruskal-Wallis test with Dunn's multiple correction. **** p < 0.0001, ***

p < 0.001, ns: not significant.

**Figure 3: MC deficient mice are resistant to *Mtb* chronic infection.**

(A) C57BL/6 and CgKitW$^{sh}$ mice were infected with a low aerosol dose (~100CFU) of *Mtb*

HN878 and mice were sacrificed at 50, 100 and 150 dpi. (B) Bacterial burden was assessed in

lungs and spleens by plating. (C) Lungs were harvested, fixed in formalin and embedded in

paraffin. H&E staining was caried out for blinded and unbiased analysis of histopathology. (D)

Representative images and the area of inflammation measured in each lobe is shown. Scale

bars: 2mm. Original magnification: ×20. Data points represent the mean ± SD of two

experiments (*n* = 8-15 per time point per group). Statistical analysis was performed using

unpaired, 2-tailed Student's t test between C57BL/6 and *CgKitW$^{sh}$* mice, **** p < 0.0001, ***

p < 0.001, * p< 0.05.

**Figure 4: MC deficient mice have dysregulated immune profile after *Mtb* infection.**

C57BL/6 and *CgKitW$^{sh}$* mice were infected with a low aerosol dose (~100CFU) of *Mtb* HN878

and mice were sacrificed at 50, 100 and 150 dpi. Number of (A) mast cells, (B) dendritic cells,

(C) recruited macrophages, (D) alveolar macrophages, (E) neutrophils and (F) monocytes were

enumerated in the lungs of *Mtb* infected mice. (G) Cytokine and chemokines production in

lung homogenates from mice, collected at 150dpi, was assessed by multiplex cytokine analysis.

Data points represent the mean ± SD of 1 of 2 individual experiments (*n* = 5-8 per time point

per group). Statistical analysis was performed using unpaired, 2-tailed Student's t test for (A)

to (F) and Two-way ANOVA Sidak's multiple comparison test for (G) between C57BL/6 and

*CgKitW^{sh}* mice, \*\*\* $p < 0.0001$, \*\* $p < 0.001$, \* $p < 0.05$. Outliers were removed from the

subsets using Grubb's outlier test.

**Figure 1**

**Figure 2**

**Figure 3**

**Figure 4**

**Figure S1: Predominance of $MC_{TS}$ in human and NHPs lung interstitium, blood vessels and bronchi.**

Healthy lung tissue and TB infected biopsies from human and NHP samples were stained for $MC_T$ (green), $MC_C$ (red). Accumulation and localization of (A) $MC_{TS}$, (B) $MC_{CS}$, and (C) $MC_{TCS}$ in healthy and TB infected human lung, and (D) $MC_{TS}$ and (E) $MC_{TCS}$ in LTBI and TB macaque lungs. Statistical analysis was performed using unpaired, 2-tailed Student's t test, *** $p < 0.0001$, ** $p < 0.001$, * $p < 0.05$.

**Figure S2: MC deficient mice have reduced numbers of activated $CD4^+$ and $CD8^+$ T cells in lung.** C57BL/6 and CgKitW$^{sh}$ mice were infected with a low aerosol dose (~100CFU) of *Mtb* HN878 and mice were sacrificed at 50, 100 and 150 dpi. Number of (A) $CD4^+$ $CD44^+$T cells, (B) $CD4^+$ $CD44^+$ $IFN\gamma^+$ T cells, (C) $CD4^+$ $CD44^+$TNF-$\alpha^+$ T cells (D) $CD4^+$ $CD44^+$ $IFN\gamma^+$ TNF-$\alpha^+$ T cells, (E) $CD8^+$ $CD44^+$T cells, (F) $CD8^+$ $CD44^+$ $IFN\gamma^+$ T cells, (G) $CD8^+$ $CD44^+$ TNF-$\alpha^+$ T cells, and (H) $CD8^+$ $CD44^+$ $IFN\gamma^+$ TNF-$\alpha^+$ T cells in the lungs of *Mtb* infected mice. Data points represent the mean $\pm$ SD of 1 of 2 individual experiments (*n* = 5-8 per time point per group). Statistical analysis was performed using unpaired, 2-tailed Student's t test between C57BL/6 and CgKitW$^{sh}$ mice, *** $p < 0.0001$, ** $p < 0.001$, * $p < 0.05$. Outliers were removed from the subsets using Grubb's outlier test.

**Figure S1**

**Figure S2**